Tratamiento de un varón con enfermedad de McArdle y muy alto riesgo cardiovascular con inhibidores de PCSK9
Marco-Benedí, V. ; Jarauta, E. (Universidad de Zaragoza) ; Pérez-Calahorra, S. ; Bea, A.M. ; Civeira, F. (Universidad de Zaragoza)
Resumen: Varón de 60 años con hiperlipidemia familiar combinada, cardiopatía isquémica y diabetes tipo 2. Desde la infancia, intolerancia al esfuerzo intenso. Se le diagnosticó enfermedad de McArdle a raíz de rabdomiólisis asociada a estatinas tras un infarto de miocardio. Desde entonces había seguido tratamiento con dieta, fibratos y ezetimiba con buena tolerancia, pero a pesar de ello las concentraciones de colesterol LDL (cLDL) eran >180 mg/dl. Se asoció al tratamiento alirocumab 150 mg subcutáneos cada 14 días, con excelente respuesta clínica y descenso de cLDL a 15 mg/dl, manteniéndose estable desde entonces. Nuestro caso demuestra que los inhibidores de PCSK9 son eficaces y seguros en pacientes con enfermedades musculares que contraindican las estatinas y que son una alternativa terapéutica ideal para este tipo de pacientes.
A 60-year-old male with familial combined hyperlipidemia, ischemic heart disease and type 2 diabetes. Since childhood, intolerance to intense exercise. The patient was diagnosed of McArdle''s disease after an episode of rhabdomyolysis associated with statins as treatment after a myocardial infarction. Since then, he had been treated with diet, fibrates and ezetimibe with good tolerance, despite this, LDL cholesterol (cLDL) remained >180 mg/dl. He started to be treated with alirocumab 150 mg/sc every 14 days, with excellent clinical response and a decrease in cLDL to 15 mg/dl. Our case shows that PCSK9 inhibitors are effective and safe in patients with muscle diseases who have statin contraindication, and they are a good therapeutic tool for these patients.
Idioma: Español
DOI: 10.1016/j.arteri.2018.11.005
Año: 2019
Publicado en: Clinica e Investigacion en Arteriosclerosis 31, 2 (2019), 89-92
ISSN: 0214-9168
Factor impacto SCIMAGO: 0.277 - Pharmacology (medical) (Q3) - Cardiology and Cardiovascular Medicine (Q3)
Tipo y forma: Article (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.
Exportado de SIDERAL (2020-06-29-11:25:05)
Visitas y descargas
A 60-year-old male with familial combined hyperlipidemia, ischemic heart disease and type 2 diabetes. Since childhood, intolerance to intense exercise. The patient was diagnosed of McArdle''s disease after an episode of rhabdomyolysis associated with statins as treatment after a myocardial infarction. Since then, he had been treated with diet, fibrates and ezetimibe with good tolerance, despite this, LDL cholesterol (cLDL) remained >180 mg/dl. He started to be treated with alirocumab 150 mg/sc every 14 days, with excellent clinical response and a decrease in cLDL to 15 mg/dl. Our case shows that PCSK9 inhibitors are effective and safe in patients with muscle diseases who have statin contraindication, and they are a good therapeutic tool for these patients.
Idioma: Español
DOI: 10.1016/j.arteri.2018.11.005
Año: 2019
Publicado en: Clinica e Investigacion en Arteriosclerosis 31, 2 (2019), 89-92
ISSN: 0214-9168
Factor impacto SCIMAGO: 0.277 - Pharmacology (medical) (Q3) - Cardiology and Cardiovascular Medicine (Q3)
Tipo y forma: Article (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material. Exportado de SIDERAL (2020-06-29-11:25:05)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles > Artículos por área > Medicina
Record created 2020-02-17, last modified 2020-06-29